神经内分泌瘤和糖尿病:哪些治疗方法和哪些影响
Rossella Mazzilli1, Virginia Zamponi2, Camilla Mancini2,3
1Unit of Endocrinology, Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy. Rossella.mazzilli@uniroma1.it.
Endocrine
|January 3, 2025
概括
神经内分泌瘤 (NET) 治疗通常会恶化糖尿病 (DM) 控制,导致高血糖症. 对NET患者来说,管理DM至关重要,在某些NET病例中,甲胺显示出潜在的抗癌作用.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 糖尿病 (DM) 和神经内分泌瘤 (NETs) 可以对彼此的预后产生负面影响.
- 了解DM和NET之间的相互作用对于患者管理至关重要.
研究的目的:
- 审查NET疗法对血糖控制和DM管理的影响.
- 评估抗糖尿病疗法对NET结果和管理的影响.
主要方法:
- 这是一篇关于PubMed,Science Direct和Google Scholar研究的叙述性综述.
- 搜索了关于NET治疗对DM的影响的研究,反之亦然.
主要成果:
- 大多数NET治疗可以损害血糖控制,导致高血糖或新发性糖尿病.
- 通过调整的抗糖尿病治疗和营养,可以有效地管理葡萄糖代谢失衡.
- 各种抗糖尿病药物对NETs的影响在很大程度上尚不清楚,尽管甲胺可能会改善胃肠道胰腺 NETs 的无进展生存率.
- 适当的DM管理对于放射/功能成像和优化NET治疗至关重要.
结论:
- NET疗法经常破坏血糖控制,需要仔细监测和管理DM.
- 在特定的NET环境中,甲胺具有潜在的抗瘤作用.
- 在NET患者中优化DM管理对于改善治疗结果和生活质量至关重要.
相关概念视频
Psychoneuroimmunology: Diabetes and Cancer
22
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
22
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150


